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ABSTRACT: Marfan syndrome (MFS) is a dominant disorder with a recognizable phenotype. In most 
patients with the classical phenotype mutations are found in the fibrillin-1 gene (FBN1) on 
chromosome 15q21. It is thought that most mutations act in a dominant negative way or through 
haploinsufficiency. In 9 index cases referred for MFS we detected heterozygous missense 
mutations in FBN1 predicted to substitute the first aspartic acid of different calcium-binding 
Epidermal Growth Factor-like (cbEGF) fibrillin-1 domains. A similar mutation was found in 
homozygous state in 3 cases in a large consanguineous family. Heterozygous carriers of this 
mutation had no major skeletal, cardiovascular or ophthalmological features of MFS. In the 
literature 14 other heterozygous missense mutations are described leading to the substitution of the 
first aspartic acid of a cbEGF domain and resulting in a Marfan phenotype. Our data show that the 
phenotypic effect of aspartic acid substitutions in the first position of a cbEGF domain can range 
from asymptomatic to a severe neonatal phenotype. The recessive nature with reduced expression 
of FBN1 in one of the families suggests a threshold model combined with a mild functional defect 
of this specific mutation.   ©2010 Wiley-Liss, Inc. 
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INTRODUCTION 
Human fibrillin-1 is a large protein of approximately 350 kD and member of a family of extracellular cysteine-
rich glycoproteins. Since 1991 mutations in the fibrillin-1 (FBN1) gene have been found to be responsible for 
Marfan syndrome (MFS; MIM# 134797) (Kainulainen et al., 1990; Dietz et al., 1991). Fibrillin-1 is characterized 
by a highly conserved modular domain organization. The most prominent domain is the Epidermal Growth Factor-
like (EGF) domain present 46 times and containing six highly conserved cysteine residues stabilizing the structure 
by three disulfide bonds. Of these EGF domains, 43 have a consensus sequence for calcium binding (cb) in the N-
terminal pocket of the domain which may mediate protein-protein interactions. The EGF domains are interrupted 
by seven transforming growth factor (TGF)-binding protein domains characterized by 8 cysteine residues involved 
in intra-domain disulfide bonds (Pereira et al., 1993; Robinson et al., 2006). In the last update of the Universal 
Marfan Database – FBN1  (UMD-FBN; http://www.umd.be) (Faivre et al., 2007) 803 different mutations are 
reported. Most of the mutations are missense mutations (56%) mainly substituting or creating a cysteine in a 
cbEGF domain. Other mutations are frameshift mutations, splice mutations and nonsense mutations. About 14% of 
mutations are recurring. 
All cbEGF domains start with a highly conserved aspartic acid, which is crucial for binding of a positively 
charged Ca
2+ ion (Whiteman et al., 2007). We have identified 10 index cases with a substitution of the first aspartic 
acid substitution of a cbEGF domain and reviewed a further 14 published cases. Most of them exhibit a complete 
MFS phenotype. Surprisingly, in one family the substitution only led to MFS in homozygous state in three family 
members, whereas 13 family members carrying the heterozygous mutation do not have Marfan syndrome after 
thorough clinical examination.  
There is still a lot of debate how mutations in FBN1 result in the MFS phenotype, but increasing evidence for 
different models is emerging. Possible explanations for the observed extreme variation in expression of the 
substitution of the first aspartic acid of a cbEGF domain are discussed. The observation of recessive inheritance of 
an expected dominant mutation also underscores the fact that mutations which are predicted to have a pathogenic 
effect, may not always lead to clinical symptoms.  
 
PATIENTS AND METHODS 
Patients 
The patients were referred for DNA analysis of the fibrillin-1 gene to confirm the clinical diagnosis of MFS. 
Case 1, 2, 5, 7, 9 and 10 fulfilled the clinical Ghent criteria (De Paepe A. et al., 1996) for the diagnosis MFS. All 
index patients fulfilled the Ghent criteria when the finding of a pathogenic mutation in FBN1 was included.  
Case 9 belongs to a large Turkish pedigree (Figure 1, III-1). She was examined at the age of 22 years. At the 
age of 6 weeks she was operated on a right sided hernia inguinalis. She was diagnosed with bilateral subluxation of 
the lenses when she was 3 years old. From that time on she has been operated several times for retinal detachments 
and lens luxation. At the age of 14 years an aortic root replacement was performed for progressive aortic root 
dilatation and aortic valve regurgitation. A spontaneous pneumothorax occurred at the age of 16 years. 
Clinical examination at the age of 18 years showed a marfanoid habitus, slight downslanting of palpebral 
fissures and a high and gothic palate. Despite long fingers, wrist and thumb signs were negative. She exhibited 
limited extension of her elbows, mild asymmetry of the chest, and bilateral flat feet. Her skin showed several striae 
on the chest, shoulders, hips and lower back. Her length was 179.5 cm (+3,7SD for Turkish descent) and an arm 
span of 175 cm (within normal limits). The brother of case 9 (III-3) was a 13 year old boy with Marfan syndrome. 
He had mild skeletal manifestations of Marfan (pes planus), a mildly dilated aortic root, ectopia lentis and dural 
ectasia with an anterior sacral meningocele. Furthermore he suffered from recurrent episodes of intracranial 
hypertension treated by drainage of cerebrospinal fluid. He has been described in a case report (Hilhorst-Hofstee et 
al., 2008). 
The third patient (II-15) died at the age of 22 years. His case history was obtained from the medical records. At 
the age of 2 years bilateral subluxation of lenses was diagnosed. He developed severe aortic and mitral valve 
regurgitation with an aneurysm of the aortic root. He had skeletal involvement and an anterior sacral meningocele. 
When he was 17 years of age an aortic root replacement was performed with reconstruction of the aortic and mitral                                                        Mutations of First Aspartic Acid of cbEGF-like Domains in FBN1 
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valve. Due to progressive aortic regurgitation, a re-operation was performed a year later. He died at the age of 22 
after a second episode of ventricular fibrillation.  
All heterozygous family members had a thorough skeletal, cardiologic and ophthalmologic examination 
including anthropometric measurements, echocardiography and slit lamp evaluation (Table 1). Only the mother 
and father of case 9 had an MRI evaluation for dural ectasia. The obtained clinical data of all family members are 
summarized in Table 1. The father of case 9 (II-6) had no clinical signs of Marfan syndrome. The mother (II-7) 
was tall, with a height on +2.5 SD but with normal body proportions. She had no other skeletal, ocular or 
cardiovascular involvement, but had several striae on the lumbar region and around the knees. Furthermore she 
suffered from spontaneous pneumothorax at the age of 21 years. An MRI-scan showed a dural ectasia at S2 with 
otherwise a normal dural sac. The father and mother of II-15 did not exhibit any signs of Marfan syndrome. None 
of the nine other heterozygous family members had a major criterion in one of the organ systems. Some were 
found to have a non-specific or minor sign. Individual II-1 has an arm span to height ratio of 1.06 and a mild 
dilatation of the abdominal aorta. II-4 had recurrent inguinal hernias but this was during a period of performing 
heavy physical labor. II-8 had an arm span to height ratio of 1.07 and bilateral flat feet. II-9 had reduced extension 
of the elbows. 
Figure 1. Pedigree of the family of case 9. Squares, male subjects; circles, female subjects. Affected subjects with a 
homozygous mutation (c.7454A>T) are represented by solid symbols. Presence or absence of the heterozygous mutation is 
represented by an open symbol with a black dot or a minus symbol respectively.
The clinical data of cases 1- 10 and published cases are summarized in Table 2 together with the molecular 
data. 
       Hilhorst-Hofstee et al.  E1918 
Table 1. Summary of the clinical features in the family of case 9 
  
III-1 
Case 
9 
III-3  II-6  II-7  II-15  I-5  I-6  I-1  II-1  II-2  II-3  II-4  II-5  II-8  II-9  II-12 
Age  at  examination  (years)  22 10 42 43  9  57 56 61 44 41 37 35 33 55 48 37 
Sex  F M M F M M F M M M F M F M F F 
                  
height  (cm)  180,9 150,5 167,1 174,4 135,0 164,0 157,5 166,0 167,5 174,5 167,0 188,5 161,0 181,0 164,7 161,0 
height SDS (for Turkish 
descent)  3,7 1,6 -1,2 2,5 -0,2  -1,7  -0,6  -1,4  -1,1 0,1 1,1 2,5 0,8 1,2 0,7 0,2 
arm  span  :  height  ratio  0,97 1,02 1,04 1,00 1,00 1,01 1,03 1,01 1,06 1,04 0,98 0,99 1,02 1,07 1,02 1,03 
sitting  height  :  height  ratio  0,515 0,488 0,536 0,513  np  0,535 0,528 0,519 0,527 0,517 0,531 0,516 0,523 0,482 0,520 0,526 
sitting  height  :  height  ratio  SDS  -0,8  -2,0 1,6 -0,8 np 1,5 0,2 0,3 1,0 0,3 0,3 0,2 0,0 -1,8  -0,4 0,0 
                  
Skeletal system  involv  involv  none  none  involv  none  none  none  none  none  none  none  none  involv  none  none 
major                  
pectus  carinatum  no no no no  yes  no no no no no no no no no no no 
pectus excavatum requiring 
surgery  no no no no no no no no no no no no no no no no 
sitting height : height ratio <2 
SD or armspan : height ratio 
>1.05 
no  yes  no no np no no no  yes  no no no no  yes  no no 
wrist  and  thumbsigns  no no no no no no no no no no no no no no no no 
scoliosis of >20
0 or 
spondylolisthesis  no no no no np no no no no no no no no no no no 
reduced extension at the elbow 
(<170
0)  yes  no no  yes  np no no no no no no no no no  yes  no 
pes  planus  yes  yes  no no  yes  no no no no no no  yes  no  yes  no no 
protrusio  acetabulae  np np np np np np np np np np np np np np np np 
                  
minor                  
pectus excavatum of moderate 
severity  no no no no  yes  no no no no no no no no no no no 
joint  hypermobility  no no no no np no no no no no no no no no no no 
highly arched palate with 
crowding  yes  no no no  yes  no no no no no no no no no no no 
facial  appearance  yes  no no no  yes  no no no no no no no no no no no 
                  
Ocular system  major  major  none  none  major  none  none  none  none  none  none  none  none  none  none  none 
major                  
ectopia  lentis  yes  yes  no no  yes  no no no no no no no no no no no 
                  
minor                  
abnormally  flat  cornea  np np np np np no no no no no no no no no no no 
increased  axial  length  of  globe  np np np np np np np np np np np np no no no no 
hypoplastic iris or ciliary 
muscle  np np no no  yes  no no no no no no no no no no no                                                        Mutations of First Aspartic Acid of cbEGF-like Domains in FBN1 
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Table 1. Continued 
 
III-1 
Case 
9 
III-3  II-6  II-7  II-15  I-5  I-6  I-1  II-1  II-2  II-3  II-4  II-5  II-8  II-9  II-12 
Cardiovascular system  major  major  none  none   major  none  none  none  involv  none  none  none  none  none  none  none 
major                  
Z-score aortic root diameter  10,5
1 4 0.3  -1.4  >2
2 -0.9 -0.8 -1.8 1.4 -1.1 -0.8 -2.9 -2.5 0.4  0.5  0.8 
dilatation ascending aorta  yes 
(arr)  yes   no  no  yes 
(arr)  no no no no no no no no no no no 
dissection  of  ascending  aorta no no no no no no no no no no no no no no no no 
                  
minor                  
mitral  valve  prolaps  yes  yes  no no  yes  no no no no no no no no no no no 
dilatation of main pulmonary 
artery  no no no no np no no no no no no no no no no no 
calcification of the mitral 
annulus < 40 years  no no no no np no no np no no no no no no no no 
dilatation or dissection of 
descending aorta < 50 years  no no np no np no no no  yes  no no no no no no no 
                  
Pulmonary system  involv  none  none  involv  none  none  none  none  none  none  none  none  none  none  none  none 
minor                  
spontanous pneumothorax or 
apical blebs  yes  no no  yes  no no no no no no no no no no no no 
                  
Skin and integument  involv  none  none  involv  np  none  none  none  none  none  involv  involv  none  none  none  none 
minor                  
striae  atrophicae  yes  no no  yes  np no no no no no  yes  no no no no no 
recurrent  or  incisional  herniae  no no no no np no no no no no no  yes
3 no no no no 
                  
Dura  np  major  none  major  np  np  np  np  np  np  np  np  np  np  np  np 
major                  
lumbosacral  dural  ectasia  np  yes  no  yes  np np np np np np np np np np np np 
                  
Family or genetic history  major
4 major
4 major
4 major
4 major
4 major
4 major
4 major
4 major
4 major
4 major
4 major
4 major
4 major
4 major
4 major
4
major                  
1st degree relative with Marfan 
syndrome  no  yes  yes  yes  no  yes  yes  no no no no no no no no no 
pathogenic mutation in FBN1 hom  hom  het het  hom  het het het het het het het het het het het 
F female; M male; involve involvement; np not performed; arr aortic root replacement; hom homozygous c.7454A>T FBN1 mutation; het heterozygous c.7454A>T FBN1 
mutation; Z-score related to body surface area and age according to Roman et al. (Roman et al., 1989); 1) aortic root measurement at the age of 14 years just before aortic root 
replacement; 2) no exact measurement available; 3) recurrent inguinal hernias during a period of heavy duty; 4) major criterion on the basis of a first degree affected family 
member or the presence of a pathogenic FBN1 mutation.      Hilhorst-Hofstee et al.  E1920 
Molecular studies 
DNA was extracted from peripheral blood or paraffin embedded tissue, using standard techniques, analyzed by 
DHPLC and direct DNA sequencing as described previously (Matyas et al., 2002). 
The reference sequence used to describe the mutations is the FBN1 cDNA GenBank reference sequence: 
NM_000138.3. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG 
translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen).  
Skin biopsies of case 1, 9 and her mother and case 10 were available. Fibroblasts were cultured and mRNA was 
isolated from confluent monolayers. For each individual two RNA isolations were performed: one cell culture of 
each was incubated with cycloheximide (0.25 mg/ml) for 4.5 hours prior to RNA isolation, to prevent possible 
nonsense mediated decay (NMD) of aberrantly spliced mRNA.  
RNA was isolated using the RNA isolation minikit (Qiagen) according to the manufacturers instructions. Full 
length single stranded cDNA was prepared with oligo-dT-primer and Superscript
TMII RT reverse trancriptase 
(Invitrogen). To detect possible splice errors, the complete coding sequence of FBN1 was analyzed by direct 
sequencing in 24 overlapping PCR fragments. The primers for overlapping fragments were positioned in different 
exons, to avoid allele dropout in case of exon skipping. For analysis of the mutation in exon 60, primers in exon 55 
(forward) and 63 (reverse) were used.  
Primer sequences are given in  Supp. Table S1. 
 
 
RESULTS 
Heterozygous mutations leading to a substitution of the first aspartic acid of a cbEGF domain were found in 
nine index cases and a homozygous mutation was found in 1 index case. These mutations and 14 comparable 
mutations described in the literature or in the UMD-FBN1 (UMD-FBN; http://www.umd.be) are listed in Table 2. 
The phenotypes were classical MFS in 15 cases, neonatal MFS in two cases, thoracic aortic aneurysm in one case 
and lens luxation with striae in one case. In four cases described in the literature the phenotype is not clear.  
The mutation was de novo in cases 2, 4, 5, and 8. In case 1, 3 and 6 parental DNA was not available. In case 1 
five sibs were tested negative for the mutation. In case 6 the parents and seven sibs had no clinical symptoms of 
MFS. Case 7 has an affected sister with the same mutation. Their father died as a consequence of his third aortic 
dissection when he was 52 years of age. He was thought to have MFS. The mother of case 10 is probably affected 
but was not molecularly tested. Of the published mutations three were de novo, three were familial and in eight 
inheritance was unknown (Table 2). 
Using DHPLC for mutation scanning of all 65 exons of FBN1, initially no mutation was found in case 9. As the 
parents are consanguineous, a recessive mutation was suspected. Testing one of the parents, a heterozygous 
mutation was detected in exon 60: c.7454A>T, leading to the amino acid substitution p.Asp2485Val. This 
mutation was found in a homozygous state in the patients III-1, III-3 and II-15. The parents (II-6 and II-7) of 
patients III-1 and III-3 are first cousins. The parents of patient II-15 are distantly related and both are related to II-6 
and II-7 (Figure 1). In the parents of patients III-1, III-3 and II-15 and 9 family members the mutation was 
heterozygous. The mutation was not detected in 1000 Caucasian and 60 Turkish control chromosomes.  
Sequence analysis of cDNA, made from mRNA from cultured fibroblasts of case 1, case 9 and her mother, and 
case 10 showed no evidence of erroneous splicing of exon 60. Treatment with cycloheximide, to prevent possible 
nonsense mediated decay of erroneously spliced mRNA, gave the same results. Fibrobasts of the other patients 
were not available.                                                        Mutations of First Aspartic Acid of cbEGF-like Domains in FBN1 
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Table 2. Published and observed missense mutations leading to the substitution of the first aspartic acid of a cbEGF domain 
Nucleotide 
change 
Amino acid 
change  Exon  cbEGF 
domain  Diagnosis  Phenotype  Reference 
Aberant 
mRNA 
splicing 
Predicted 
aberant 
mRNA 
splicing
a
Inheritance 
c.1468G>T   p.Asp490Tyr  11  #3  Classical MFS  ard, el, sk  (Hayward and Brock, 1997)  np  yes  Unknown 
c.2168A>C   p.Asp723Ala  18  #7  Severe classical MFS  ard, mvp, el, myop, sk (Dietz et al., 1993)  np  no  De novo 
c.2168A>T  p.Asp723Val  18  #7  Classical MFS  ard, mvp, el, sk, myop (Katzke et al., 2002)  np  no  De novo 
c.2728G>A p.Asp910Asn  22  #10  Classical  MFS  unknown  UMD  np  yes  Unknown 
c.3209A>G p.Asp1070Gly  26  #12  Neonatal  MFS  unknown  UMD  np  no  Unknown 
c.3338A>G  p.Asp1113Gly  27  #13  Phenotype unknown  unknown  (Liu et al., 1997)  np  no  Unknown 
c.3463G>A  p.Asp1155Asn  27  #14  Thoracic aortic aneurysm  ard, mvp, diss  (Milewicz et al., 1996)  no  yes  De novo 
c.3464A>G  p.Asp1155Gly  28  #14  Classical MFS  ard, el  Case 1  no no  Parents not available, 5 
sibs neg for mutation 
c.3712G>A  p.Asp1238Asn  29  #16  Phenotype unknown  unknown  (Yuan et al., 1999)  np  no  Unknown 
c.3713A>G p.Asp1238Gly  30  #16  Classical  MFS  ard,  mvp, sk  (Tiecke et al., 2001)  np  no  Familial 
c.3964G>A  p.Asp1322Asn  31  #18  Neonatal MFS  ard, mi, ti, myop, sk  Case 2  np yes  De  novo 
c.4210G>T  p.Asp1404Tyr  33  #20  Classical MFS  ard, el, sk  (Hayward et al., 1997)  yes  yes  Familial 
c.5422G>C  p.Asp1808His  43  #26  Lens luxation and striae  el, str  Case 3  np  no  Parents not available 
c.5671G>A  p.Asp1891His  45  #28  Classical MFS  ard, sk  Case 4  np no  De  novo 
c.5788G>C  p.Asp1930His  45  #29  Classical MFS  ard, el, sk  Case 5  np yes  De  novo 
c.5788G>A  p.Asp1930Asn  46  #29  Phenotype unknown  unknown  (Liu et al., 1997)  np  yes  Unknown 
c.5788G>A  p.Asp1930Asn  46  #29  Classical MFS  ard, el, sk, de, str  Case 6  np  yes  Parents not available 
c.6037G>T  p.Asp2013 Tyr  48  #31  Classical MFS  ard, el, sk, de, str  Case 7  np yes  Familial 
c.6379G>T  p.Asp2127Tyr  51  #32  Classical MFS  ard, el  (Matsukawa et al., 2001)  np  yes  Familial 
c.6381T>A  p.Asp2127Glu  52  #32  Classical MFS  ard, sk  (Kainulainen et al., 1994)  np  no  Familial 
c.7331A>G  p.Asp2444Gly  59  #38  Classical MFS  ard, sk  Case 8  np no  De  novo 
c.7454A>T  p.Asp2485Val  60  #39  Classical MFS in 
homozygous state  ard, el, sk, str, her, pn  Case 9  no  no  Familial 
c.7819G>A  p.Asp2607Asn  62  #42  Classical MFS  ard, mvp, sk  Case 10  no  no  Mother suspect for MFS 
c.7820A>G  p.Asp2607Gly  63  #42  Phenotype unknown  unkown  (Liu et al., 1997)  np  no  Unknown 
UMD Universal Marfan Database – FBN1 (UMD-FBN; http:/www.umd.be); cbEGF calcium binding Epidermal Growth Factor domain; bp basepair; np not performed; neg 
negative; pos positive; ard aortic root dilatation; diss aortic dissection; mvp mitral valve prolapse, mi mitral valve insufficiency; el ectopia lentis; pal high arched palate; ti 
tricuspid valve insufficiency; myop high myopia; ar arachnodactyly; hm hypermobility; contr contractures; str striae; her hernia; sk skeletal involvement; de dural ectasia; pn 
pneumothorax; unknown. The gray row represents the recessive mutation described in this article. 
Mutation numbering refers to the FBN1 cDNA GenBank reference sequence: NM_000138.3, with the A of the ATG translation initiation codon as nucleotide +1 
(www.hgvs.org/mutnomen).
 a) Alamut mutation interpretation software version 1.5; Interactive Biosoftware, Rouen France.       Hilhorst-Hofstee et al.  E1922 
DISCUSSION 
We identified a heterozygous substitution of the first aspartic acid of a cbEGF domain in FBN1 in nine index 
patients and a homozygous substitution in one index patient with MFS. Reviewing the literature we found 12 
reports of substitution of the first aspartic acid, and a further two unpublished cases are quoted in the UMD 
database (UMD-FBN; http://www.umd.be) (Collod-Beroud et al., 2003) as summarized in Table 2. All 10 index 
patients found in our center fulfilled the Ghent criteria when the finding of a pathogenic mutation was included. Of 
the 14 published cases, eight were reported to have a classical Marfan phenotype, one was a neonatal Marfan and 
one had a thoracic aortic aneurysm. Of four cases the phenotype was not reported. In all cases the acidic amino 
acid aspartic acid is replaced by a nonpolar or noncharged polar amino acid, apart from one mutation where 
aspartic acid is replaced by another acidic amino acid (p.Asp2127Glu) (Kainulainen et al., 1994). The codons of 
the first aspartic acids in the cbEGF domains always contain the last base of one exon and the first two bases of the 
next. Consequently, mutations of these codons may affect splicing. Aberrant splicing was excluded in cases 1, 9, 
and 10 and in one of the published cases (Milewicz et al., 1996). The mutation c.4210G>T was shown to destroy a 
donor splice site with abnormal splicing as a consequence (Hayward et al., 1997). Of the 19 cases in which no 
cDNA analysis was performed, prediction software predicted aberrant splicing in eight cases (Table 2). Exon 
skipping, as a result of these mutations, may have more severe effects than missense mutations, because the exons 
are all in frame and consequently, skipping will lead to a shorter protein that may exert a dominant negative effect 
(Robinson et al., 2002).  
There are several reasons to argue that a substitution of the first aspartic acid of a cbEGF domain will lead to a 
MFS phenotype in the heterozygous state. Calcium binding of cbEGF domains is necessary for stabilization of the 
secondary structure, prevention of proteolytic degradation and for protein-protein interaction (Dietz et al., 1993; 
Handford et al., 1991; Cooke et al., 1987). The first aspartic acid of a cbEGF domain is highly conserved in 
evolution and in the human fibrillin-1 gene all cbEGF domains start with an aspartic acid, which is crucial for 
binding of a positively charged Ca
2+ ion (Figure 2) (Whiteman et al., 2007). Furthermore mutations of the first 
amino acid of a cbEGF domain of coagulation factor IX in haemophilia B have been proven to reduce calcium 
binding even if the aspartic acid is replaced by the acidic amino acid glutamic acid (Handford et al., 1991; Winship 
and Dragon, 1991). The finding of 23 MFS or MFS-like cases with a heterozygous substitution of an aspartic acid 
in this position of the cbEGF domain underscores the crucial role of this amino acid. In this view the recessive 
nature of the mutation p.Asp2485Val in the family of case 9 came as a surprise. The family of case 9 (Figure 1) 
has been thoroughly investigated. Patients III-1 (case 9), III-3 and II-15 have the classical type of Marfan 
syndrome according to the Ghent criteria (De Paepe A. et al., 1996). Based on the pedigree with three affected 
patients and healthy consanguineous parents recessive inheritance could be expected. This was confirmed by 
finding a homozygous missense mutation in all three affected patients. The four unaffected parents and nine other 
unaffected relatives were found to be carriers of the mutation. Unexpectedly in none of the investigated 
heterozygous carriers obvious signs of Marfan syndrome could be found. Only after thorough clinical examination 
one of them (II-7) was found to have a dural ectasia at S2, which as yet is considered a major symptom in the 
Ghent criteria. Together with the family history and some minor signs (pneumothorax, striae and reduced 
extension of the elbows) this classifies II-7 as having Marfan syndrome. However, compared to the homozygous 
cases, the cardinal Marfan features in the skeletal, cardiac and ophthalmological systems are absent. 
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Figure 2. Class I cbEGF domain showing the position of the first Asp in relation to the calcium molecule. 
(A) 3D picture of a cbEGF domain of fibrillin-1. The yellow arrow points to the first Asp. Picture derived 
from the NCBI database (http://www.ncbi.nlm.nih.gov/) (Downing et al., 1996). (B) cbEGD like domain 
(Handford et al., 1991). The arrow points to the first aspartic acid residue. Solid lines are the disulphide 
bridges between cysteine residues. 
 
To our knowledge very little is known about recessive FBN1 mutations. Only one family has been reported in 
which Marfan syndrome was found in two affected cousins homozygous for a FBN1 mutation while the four 
normal parents were heterozygous carriers, indicating recessive inheritance of the syndrome (De Vries et al., 
2007). The mutation is located in exon 11 and leads to an amino-acid substitution creating a cysteine. Like us the 
authors expected this mutation to have a dominant effect in the heterozygous state. Two of the parents were sibs 
and exhibited minor signs of Marfan syndrome (increased arm span to height ratio and a highly arched palate). No 
other family members have been investigated. Only one other probably recessively inherited form of Marfan 
syndrome has been described but could not be proven by molecular analysis as the gene was not yet known (Fried 
and Krakowsky, 1977). 
Three families have been described in the literature in which both parents are affected with more severely 
affected children. The first is an Italian couple of first cousins, both affected with Marfan syndrome, who had 4 
affected children. Two of the four affected children showed more severe manifestations than other affected family 
members, presumably due to homozygosity (Capotorti L. et al., 1959). In 1984, Chemke described a family with 
Marfan syndrome. Two sibs suffered from a severe phenotype reminiscent of neonatal Marfan syndrome. Their 
parents were cousins and had a much milder phenotype. Remarkable is that the probably homozygous sibs were 
the only patients in the family with ectopia lentis (Chemke et al., 1984). In 1988 a severely affected boy has been 
described (Schollin et al., 1988). Both parents were affected and were found to carry a missense mutation in FBN1. 
Compound heterozygosity was identified in the severely affected child (Karttunen et al., 1994).  
In the recessive family described here the heterozygous mutation does not exert an important effect on the 
phenotype. Only in the homozygous state the abnormal fibrillin causes the classical clinical phenotype of Marfan 
syndrome. This observation together with the few other described families with bi-allelic inheritance, may support 
both alternative pathogenetic models of Marfan syndrome. A dominant negative effect of FBN1 mutations has 
been the leading hypothesis for the pathogenesis of Marfan syndrome for a long time. However, several 
manifestations of Marfan syndrome like bone overgrowth, craniofacial features, lung disease, and muscle and fat 
hypoplasia could not be explained by a structurally abnormal protein. The observation that fibrillin interacts with a 
variety of proteins, including the latent TGFβ binding proteins (LTBP’s) has lead to several investigations       Hilhorst-Hofstee et al.  E1924 
indicating that fibrillin-1 can interact with TGFβ signaling (Annes et al., 2003; Azhar et al., 2003; Isogai et al., 
2003; Hubmacher et al., 2006; Kaartinen and Warburton, 2003; Loeys et al., 2006; Neptune et al., 2003; Ng et al., 
2004; Ten Dijke and Arthur, 2007). 
According to splice site prediction software (Alamut mutation interpretation software version 1.5; Interactive 
Biosoftware, Rouen, France) the c.7454A>T mutation, found in the family described here, is not predicted to cause 
erroneous splicing. This was confirmed by cDNA studies, showing no evidence of splice error. The position of the 
mutation (exon 60) may explain the lack of expression as mutations in the more C-terminal end of the gene are 
expected to give a milder phenotype (Faivre et al., 2007; Robinson et al., 2002). However the mutation in case 10 
is even more terminal and still leads to a classical MFS phenotype. 
Hutchinson et al. (Hutchinson et al., 2003) hypothesized that variable expression of the normal FBN1 allele 
could moderate the phenotypic effect of the mutant allele. A compensatory higher level of FBN1 expression from 
the normal allele would explain a milder phenotype. As the normal alleles are inherited from 5 different parents in 
our recessive family, this mechanism is highly unlikely.  
We hypothesize that the p.Asp2485Val mutation acts as a hypomorphic allele with a minimal dominant 
negative effect. Reduction of gene expression of both alleles could be the main determinant of the phenotype in 
homozygotes. The observation of only one major clinical sign in one of the heterozygotes (dural ectasia in II-7, 
Figure 1) and no major clinical signs in 12 other heterozygotes could be explained by sufficient gene expression 
with only a mild functional defect of the mutant allele product. This was also shown in a mouse model, however in 
this model the mutation had a severe dominant negative effect (Pereira et al., 1997). In this model with a deletion 
of 272 amino acids in the central part of fibrillin-1, a tenfold reduction in expression of the mutant allele was 
shown in heterozygous mice, resulting in a normal phenotype. Homozygous mutant mice however died shortly 
after birth due to severe vascular complications. The other mouse model of Pereira was a targeted FBN1 mutation 
leading to 15% expression of a normal product with no abnormal phenotype in heterozygous mice, while mice 
homozygous for this mutation have severe abnormalities comparable with the neonatal MFS phenotype. These 
mouse models suggests that there is a threshold of expression of the normal allele below which the abnormal 
phenotype will develop (Pereira et al., 1999; Dietz and Mecham, 2000). 
To understand the exact pathogenetic mechanism expression studies and studies on protein synthesis, secretion 
and matrix incorporation of the Asp2486Val mutation are necessary For comprehensive studies of this type, a 
mouse model should be created. 
The finding of a homozygous substitution of A>T, as described here, has implications for mutation screening in 
MFS. Homozygous substitutions will not have an effect on denaturation of double stranded DNA, because the 
basepair remains the same. Consequently, heteroduplex based testing, such as DHPLC, working with the principle 
of differential denaturation of double stranded heteroduplex DNA, cannot detect this mutation in homozygous 
state. Formerly, based on the presumed dominant inheritance mode, only heterozygous mutations were expected. 
Now it is clear that recessive inheritance is also possible and mutations may have been missed in similar cases, 
because heteroduplex based testing has been used until recently in many large diagnostic centers. Most 
laboratories nowadays use direct sequencing, which avoids this problem. 
In conclusion we have shown that the first aspartic acid of a cbEGF domain in FBN1 is important for the 
function of fibrillin-1, but may not always lead to a clinical effect in the heterozygous state. This underscores that 
missense mutations must be interpreted with care. 
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Supp. Table S1. Primers for cDNA sequencing of FBN1: F=forward; R=reverse; numbers refer to position 
in cDNA sequence 
fragment  primername  Sequence 5’ > 3’  Length bp 
1  FBN1F1 ATGCGTCGAGGGCGTCTGCT  384 
  FBN1R384 GCTACCTCCATTCATACAGCGA   
2  FBN1F318 GATAGCTCCTTCCTGTGGCTCC  406 
  FBN1R728 CCGTGCGGATATTTGGAATG   
3  FBN1F657 CCCCTGTGAGATGTGTCCTG  407 
  FBN1R1064 TTGGTTATGGACTGTGGCAGC   
4  FBN1F1012 ACAGCTCTGACAAACGGGCG  384 
  FBN1R1396 TGCAGCGTCCATTTTGACAG   
5  FBN1F1358 GCCAGTTGGTCCGCTATCTC  330 
  FBN1R1688 ACATGAAAGCCCGCATTACAC   
6  FBN1F1609 AATGGCCGGATCTGCAATAA  398 
  FBN1R2007 CTGGCCTCTCTTGTATCCACCA   
7  FBN1F1927 CTGGCTGTGGGTCTGGATGG  362 
  FBN1R2289 GCAGTTTTTCCCAGTTGAATCC   
8  FBN1F2212 ATCTGTGAAAACCTTCGTGGGA  399 
  FBN1R2611 AGGTGGCTCCATTGATGTTGA   
9  FBN1F2458 GTCTGCAAGAACAGCCCAGG  357 
  FBN1R2815 TGGGACACTGACACTTGAATGA   
10  FBN1F2699 TACTCAAGAATTAAAGGAACA  525 
  FBN1R3224 CGGCATTCGTCAATGTCTGTGC   
11  FBN1F3141 CATTGGCAGCTTTAAGTGCAGG  460 
  FBN1R3621 ACCACCATTCATTATGCTGCA   
12  FBN1F3558 CCATTCAACTCCCGATAGGCT  335 
  FBN1R3893 TTTTCACAGGTCCCACTTAGGC   
13  FBN1F3783 CAGGTGCTTGTGTTATGATG  392 
  FBN1R4173 GCACAGACAGCGGTAAGA   
14  FBN1F4062 GATTGGAGATGGCATTAAGTGC  451 
  FBN1R4513 TGTTGACACAGTTCCCACTGA   
15  FBN1F4425 CTACGAACTGGACAGAAGCGG  593 
  FBN1R5018 ATACAGGTGTAGTTGCCAACGG   
16  FBN1F4910 ACTACCTGAATGAAGATACACG  626 
  FBN1R5536 GACCTGTGGAGGTGAAGCGGTAG   
17  FBN1F5348 TCAACATGGTTGGCAGCTTCC  476 
  FBN1R5824 AAAGATTCCCATTTCCACTTGC   
18  FBN1F5722 ACAATTGGTTCCTTCAACTG  356 
  FBN1R6074 GCACAAATTTCTGGCTCTT   
19  FBN1F5973 CTTGGATGGGTCCTACAGATGC  579 
  FBN1R6552 CACATTCTTGCAGGTTCCATT   
20  FBN1F6466 GGTTATACTCTAGCGGGAATG  450 
  FBN1R6937 TCCCACGGGTGTTGAGGCAGCG  
21  FBN1F6842 AGCGGAGACCTGATGGAGAGG  645 
  FBN1R7487 CAGTTGTGTTGCTTGGTTGCA   
22  FBN1F7429 CAAGAGGATGGAAGGAGCTGC  476 
  FBN1R7905 GAACTGTTCATACTGGAAGCCG   
23  FBN1F7785 CTACCTCCAGCACTACCAGTGG  384 
  FBN1R8169 GTAGCCATTGATCTTACACTCG   
24  FBN1F8024 CACCTGGTTACTTCCGCATAGG  672 
  FBN1R8696 ATGATTCTGATTGGGGGAAAA   
 